These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24515703)

  • 21. Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine.
    Gambassi G; Capurso S; Tarsitani P; Liperoti R; Bernabei R
    Aging Clin Exp Res; 2006 Jun; 18(3):266-70. PubMed ID: 16804375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Case Report: Atypical Neuroleptic Malignant Syndrome on Clozapine and Mood Stabilizers.
    Amador EC; Kassam A; Hopp C; Cunningham EA
    J Clin Psychopharmacol; 2019; 39(5):518-519. PubMed ID: 31425460
    [No Abstract]   [Full Text] [Related]  

  • 23. Disseminated intravascular coagulopathy and thrombocytopenia associated with clozapine-induced neuroleptic malignant syndrome.
    Lowy A; Wilson A; Sachdev P; Lindeman R
    Aust N Z J Med; 1995 Aug; 25(4):368. PubMed ID: 8540883
    [No Abstract]   [Full Text] [Related]  

  • 24. Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine.
    Paparrigopoulos T; Tzavellas E; Ferentinos P; Mourikis I; Liappas J
    World J Biol Psychiatry; 2009; 10(1):70-3. PubMed ID: 19673089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroleptic malignant-like syndrome and acute hepatitis during tolcapone and clozapine medication.
    Blum MW; Siegel AM; Meier R; Hess K
    Eur Neurol; 2001; 46(3):158-60. PubMed ID: 11598337
    [No Abstract]   [Full Text] [Related]  

  • 26. Neuroleptic malignant syndrome associated with long-term clozapine treatment: report of a case and results of a clozapine rechallenge.
    Huang TL
    Chang Gung Med J; 2001 Aug; 24(8):522-5. PubMed ID: 11601195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases.
    Sachdev P; Kruk J; Kneebone M; Kissane D
    J Clin Psychopharmacol; 1995 Oct; 15(5):365-71. PubMed ID: 8830069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroleptic malignant syndrome: an experience of four cases.
    Desai ND; Mundra VK; Gore YS; Diwan PJ; Jaydeokar SS; Jain V; Sutharsan R; Agarwal A; Moulick ND; Manocha SM
    J Assoc Physicians India; 1998 Jul; 46(7):653-4. PubMed ID: 12152854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Malignant neuroleptic syndrome and polyserositis associated to clozapine use: report of one case].
    Eymin G; Andresen M; Godoy J; Rada G
    Rev Med Chil; 2005 Oct; 133(10):1225-8. PubMed ID: 16341374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Caution is still needed when prescribing atypical antipsychotics.
    Carey S
    Br J Hosp Med (Lond); 2008 May; 69(5):299. PubMed ID: 18557562
    [No Abstract]   [Full Text] [Related]  

  • 31. Clozapine: new preparation. A last resort for parkinsonian patients with psychosis.
    Prescrire Int; 2002 Feb; 11(57):1-6. PubMed ID: 11985366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful clozapine rechallenge following prior intolerance to clozapine.
    Cohen SA
    J Clin Psychiatry; 1994 Nov; 55(11):498-9. PubMed ID: 7989287
    [No Abstract]   [Full Text] [Related]  

  • 33. It's all atypical: can clozapine cause atypical neuroleptic malignant syndrome?
    Nama S; Aftab M
    Aust N Z J Psychiatry; 2012 Mar; 46(3):280-1. PubMed ID: 22391291
    [No Abstract]   [Full Text] [Related]  

  • 34. Multiple re-challenges for clozapine neutropenia in Parkinson's disease.
    Komaragiri A; Friedman JH
    Parkinsonism Relat Disord; 2016 Feb; 23():114-5. PubMed ID: 26717858
    [No Abstract]   [Full Text] [Related]  

  • 35. Neuroleptic malignant syndrome associated with clozapine use.
    Anderson ES; Powers PS
    J Clin Psychiatry; 1991 Mar; 52(3):102-4. PubMed ID: 2005071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient.
    Bottlender R; Jäger M; Hofschuster E; Dobmeier P; Möller HJ
    Pharmacopsychiatry; 2002 May; 35(3):119-21. PubMed ID: 12107858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three potentially fatal adverse effects of psychotropic medications.
    Wren P; Frizzell LA; Keltner NL; Wright AV
    Perspect Psychiatr Care; 2003; 39(2):75-81. PubMed ID: 12894601
    [No Abstract]   [Full Text] [Related]  

  • 38. Clozapine Rechallenge Following Neuroleptic Malignant Syndrome: A Systematic Review.
    Lally J; McCaffrey C; OʼMurchu C; Krivoy A; Guerandel A; MacCabe JH; Gaughran F
    J Clin Psychopharmacol; 2019; 39(4):372-379. PubMed ID: 31205196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clozapine-induced neuroleptic malignant syndrome: an interaction between dopaminergic and purinergic systems?
    Lara DR; Wolf AL; Lobato MI; Baroni G; Kapczinski F
    J Psychopharmacol; 1999; 13(3):318-9. PubMed ID: 10512095
    [No Abstract]   [Full Text] [Related]  

  • 40. Clozapine-induced neuroleptic malignant syndrome: another inconclusive case report.
    Weller M; Kornhuber J
    Aust N Z J Med; 1996 Apr; 26(2):232-3. PubMed ID: 8744626
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.